Jeena Sikho Lifecare Ltd (NSE: JSLL, BSE: 544476) is a Zirakpur, Punjab-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,506 Cr, it ranks #887 by market cap among the 6,197 Indian listed companies on FinBizNet, and #29 of 86 in Medicinal Chemicals and Botanical Products. At ₹343.50 (as of 16 Nov 2026), the share price is 57.5% below its 52-week high of ₹809.00 and 8.9% above its 52-week low of ₹315.35. The share price is down 56.9% over one year and down 35.4% over three months.
| Current Price | ₹343.50 |
|---|---|
| Market Cap | ₹4,506 Cr |
| NSE Symbol | JSLL |
| BSE Code | 544476 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 20.6 |
| Return on Equity | 59.92% |
| Return on Assets | 34.56% |
| 52-Week Range | ₹315.35 – ₹809.00 |
| 1-Year Price Change | -56.9% |
| 3-Month Price Change | -35.4% |
| Beta (1Y) | 0.28 |
| Dividend Yield | 1.22% |
| Headquarters | Zirakpur, Punjab |
| Website | jeenasikho.com |
| Revenue | ₹235 Cr |
|---|---|
| Net Profit | ₹37 Cr |
| Net Margin | 15.6% |
| EPS (Basic) | ₹2.95 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Jeena Sikho Lifecare Ltd reported revenue of ₹235 Cr in Q2 FY27, up 23.9% from ₹190 Cr in Q2 FY26 and up 4.8% from ₹224 Cr in Q1 FY27. It posted a net profit of ₹37 Cr for the quarter, against a net profit of ₹59 Cr in Q2 FY26 (down 37.7%). Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹174 Cr (Q1 FY26) to ₹235 Cr (Q2 FY27). The company was profitable in each of these 6 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹235 Cr | ₹37 Cr | 15.6% |
| Q1 FY27 | ₹224 Cr | ₹66 Cr | 29.4% |
| Q4 FY26 | ₹216 Cr | ₹45 Cr | 20.9% |
| Q3 FY26 | ₹222 Cr | ₹67 Cr | 30.0% |
| Q2 FY26 | ₹190 Cr | ₹59 Cr | 30.9% |
| Q1 FY26 | ₹174 Cr | ₹51 Cr | 29.4% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 63.67% of Jeena Sikho Lifecare Ltd's shares as of Sept 2026, against 63.61% in Sept 2025 (+0.06 percentage points). Delivery averaged 44.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Jeena Sikho Lifecare Limited trades in ayurvedic medicines in India. The company offers ayurvedic products under the Shuddhi brand name. It also provides services, including in-patient, out-patient, 72 hours health camps, Panchakarma therapies, dietary support and nutrition guidance, home-based healthcare services, and healthcare support centre services. In addition, the company operates clinics under the Shuddhi Ayurveda, Shuddhi Clinics, Hospital & Institution of Integrated Medical Sciences, Shuddhi Wellness Clinics & Hospital, Shuddhi Ayurveda Panchakarma Hospital, and Shuddhi Panchakarma Day Care Clinic names. Jeena Sikho Lifecare Limited was founded in 2009 and is headquartered in Zirakpur, India.
1. Trading of Ayurvedic Medicines-This segment deals in the trading of trading of ayurvedic medicines.
1. Ayurvedic Products/Medicines-51.9% 2. Ayurvedic Healthcare Services-47.8% 3. Others-0.3%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Jeena Sikho Lifecare Ltd | ₹4,506 Cr | 20.6 | 59.92% | ₹235 Cr | -56.9% |
Listed by market capitalisation. Ratios are shown for context only.
Jeena Sikho Lifecare Ltd is trading at ₹343.50, with a market capitalisation of ₹4,506 Cr.
Jeena Sikho Lifecare Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Jeena Sikho Lifecare Ltd has a P/E of 20.6 and a return on equity of 59.92%.
Jeena Sikho Lifecare Ltd is listed on the NSE under the symbol JSLL and on the BSE under the scrip code 544476.
Jeena Sikho Lifecare Ltd's share price is down 56.9% over one year and down 35.4% over three months. Its 52-week range is ₹315.35 to ₹809.00.
In Q2 FY27, Jeena Sikho Lifecare Ltd reported revenue of ₹235 Cr and net profit of ₹37 Cr, with basic EPS of ₹2.95 (consolidated, parsed from the company's exchange filing).
Jeena Sikho Lifecare Ltd reported revenue of ₹235 Cr in Q2 FY27, up 23.9% from ₹190 Cr in Q2 FY26 and up 4.8% from ₹224 Cr in Q1 FY27.
Promoters held 63.67% of Jeena Sikho Lifecare Ltd's shares as of Sept 2026, against 63.61% in Sept 2025 (+0.06 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.